Epidemiology and Global Burden
Human papillomavirus (HPV) is the most common sexually transmitted infection worldwide; over 80% of sexually active adults will be exposed during their lifetimes 2. More than 200 HPV types have been identified. Twelve HPV types are generally classified as high-risk carcinogenic types. HPV16, 18, 31, and 45 account for the majority of HPV-attributable cancers globally 2.
In the United States, the CDC reports approximately 49,908 new HPV-associated cancers annually (2018–2022), of which 39,300 (79%) are HPV-attributable and a striking 36,400 (93% of HPV-attributable cases) are estimated to be preventable by the 9-valent vaccine 1. Table 1 summarizes the US cancer distribution by anatomical site and sex.
Table 1. US HPV-Associated Cancer Distribution (2018–2022)
| Site | Female Share | Male Share | HPV Attributability |
|---|---|---|---|
| Cervix | 46% of female HPV cancers | — | ~90% |
| Anus | 21% | Significant | ~90% |
| Oropharynx | 14% | Predominant male site | ~70% |
| Vulva/Vagina | 19% combined | — | ~70% |
| Penis | — | Present | ~60% |
Globally, cervical cancer was the eighth most common malignancy and ninth leading cause of cancer-related death as of the 2022 WHO Global Cancer Observatory 2. It remains the second most common cancer in African and Southeast Asian women (after breast cancer). Oropharyngeal cancer, with 106,400 incident cases worldwide, is the 24th most common cancer, approximately 70% HPV-attributable 2. A notable epidemiological trend is the rising incidence of HPV-positive oropharyngeal cancer in high-income countries—predominantly among White males in the US—while cervical cancer burden remains concentrated in low- and middle-income countries (LMICs) 12.
Racial/ethnic disparities in the US are pronounced: non-Hispanic American Indian/Alaska Native women bear the highest cervical cancer incidence (16.1 per 100,000), compared with 14.6 per 100,000 in non-Hispanic White women and 7.3 per 100,000 in non-Hispanic Asian/Pacific Islander women 1. In India, the pooled HPV prevalence in head and neck cancers is 20% (95% CI, 12–32), with HPV-attributable fractions of 12.5% in oropharyngeal and 3.4% in oral cancers 12. In South Africa, increasing HIV prevalence is driving rising HPV16 E6 seropositivity in noncervical HPV-related cancers over time (adjusted prevalence ratio 1.84 for 2010–2016 vs. 1995–2006) 13.
Etiology and Pathogenesis
Approximately 90% of HPV infections resolve spontaneously within 12–24 months 2. Persistent infection with high-risk types leads to cervical intraepithelial neoplasia (CIN) and, ultimately, invasive cancer. The two principal oncoproteins, E6 and E7, drive carcinogenesis by disrupting p53 (via E6-mediated degradation) and the retinoblastoma protein Rb (via E7 binding), abrogating cell-cycle arrest and apoptosis 18.
At the molecular level, HPV DNA integration—characteristically at the E1/E2 region—disrupts the viral polyadenylation signal, enabling E6/E7 transcript stabilization via a downstream host polyadenylation signal. Crucially, despite multiple integrated HPV copies in cancer tissues, only a single integrated copy drives detectable E6/E7 oncogenic RNA expression in cell lines such as CaSki, SiHa, and HeLa 5. Virus–host fusion transcripts with therapeutic relevance have been identified; silencing the host portion of these transcripts stabilizes p53, inhibits proliferation, and promotes senescence 5.
Additional oncogenic mechanisms include HPV16 E7-mediated downregulation of miR-23a, leading to upregulation of HOXC8 and enhanced cervical cancer cell viability and migration 6. The receptor tyrosine kinase ErbB2 (HER2) also regulates HPV long control region promoter activity via Akt and ERK signaling; ErbB2 depletion significantly reduces E6 and E7 transcript levels, positioning ErbB2 as a potential therapeutic target 7.
A Korean retrospective cohort study (2010–2021, n=1,757) demonstrated that vaccination reduced HPV16 viral load by 6-fold, increased the episomal-to-integrated viral DNA ratio, and shortened infection duration: HPV16 infections lasting >18 months decreased from 31.0% to 21.6% with vaccination 4. Key cofactors accelerating progression include HIV/immunosuppression, tobacco smoking (adjusted IRR for HPV-positive oropharyngeal cancer in ever-smokers vs. never-smokers: 2.6) 30, oncovirus coinfections 20, and recent evidence linking SARS-CoV-2 infection with significantly elevated risk of multiple HPV-related malignancies (cervical +67%, vaginal +131%, vulvar +98%, anal +92%, oropharyngeal +78%) 19.
Prevention
Primary Prevention: Vaccines
Three prophylactic vaccines are available: bivalent (HPV16/18), quadrivalent (HPV6/11/16/18), and 9-valent (HPV6/11/16/18/31/33/45/52/58). The 9-valent vaccine targets genotypes responsible for 93% of preventable US HPV-associated cancers 1. A Scottish population-based study of women vaccinated at age 12–13 demonstrated zero cases of invasive cervical cancer (100% efficacy) 2. Meta-analysis shows an 82.7% relative reduction in oral/oropharyngeal HPV infection and a significant reduction in anal cancer incidence (RR = 0.42) among vaccinated individuals 2.
The WHO's December 2022 position paper incorporates single-dose schedules, endorsed by SAGE in April 2022 3. As of June 2025, 75 countries have adopted single-dose HPV vaccination 35, representing a major equity-advancing policy shift. Global coverage reached 56.9% among 9–14-year-old girls in 2024, recovering from a pandemic-era nadir of 44.4% in 2021 (AAPC +8.8% from 2021–2024) 36. However, only 46% of low-income countries have introduced HPV vaccination nationally, versus 98% of high-income nations, and the Eastern Mediterranean region achieves only 19.5% coverage 36.
Secondary Prevention: Cervical Screening
HPV DNA testing is the preferred primary screening modality; the FDA approved self-collection of vaginal samples using the Onclarity (Becton Dickinson) and cobas (Roche) HPV tests in health care settings on May 17, 2024 3738. The NCI's SHIP Trial Network, launched in early 2024, is evaluating home-based self-collection. DNA methylation markers are emerging as triage tools, with HPV-positive/methylation-negative women demonstrating lower cumulative cervical cancer incidence than cytology-negative women 40. In women living with HIV, the International Papillomavirus Society endorses HPV DNA (not RNA) testing as the preferred screening approach 23.
Treatment of HPV-Associated Cancers
Cervical Cancer
In April 2024, the FDA granted traditional approval to tisotumab vedotin-tftv (Tivdak) for recurrent or metastatic cervical cancer following progression on prior chemotherapy. The pivotal innovaTV 301 phase III trial (n=502) demonstrated superior overall survival (11.5 vs. 9.5 months; HR 0.70, p=0.0038), progression-free survival (4.2 vs. 2.9 months; HR 0.67, p<0.0001), and confirmed ORR (17.8% vs. 5.2%, p<0.0001) versus chemotherapy 17. Concurrent chemoradiation with brachytherapy remains the standard for locally advanced disease; bevacizumab combined with platinum-based chemotherapy and pembrolizumab continues in front-line metastatic settings.
Anal Cancer
Chemoradiation (mitomycin-C/5-FU with radiation) remains the standard of care for locally advanced anal squamous cell carcinoma. For metastatic disease, carboplatin/paclitaxel is first-line; PD-1 inhibitors pembrolizumab and nivolumab are established in later lines. A phase II trial of pembrolizumab monotherapy in 32 patients with advanced anal cancer yielded a modest ORR of 9.4% and median OS of 13.6 months; notably, rare long-term complete responders (2.5–8 years) were all HPV-positive and lacked liver metastases 16. Circulating TTMV-HPV DNA has emerged as a predictive biomarker, with early decreases by week 6 correlating with improved PFS (HR 0.37, p=0.04) 16. Phase 3 trials of front-line chemo-immunotherapy and post-chemoradiation ICI consolidation are ongoing 25.
Oropharyngeal Cancer
HPV-positive oropharyngeal cancer carries a substantially better prognosis than HPV-negative disease. Dual p16/HPV testing—with HPV RNA PCR as the most accurate diagnostic modality—is now recommended for all oropharyngeal cancers, particularly in smokers and regions with high discordant rates; p16+/HPV– discordant cases show significantly poorer prognosis 32. De-escalation clinical trials (reducing chemoradiation intensity in HPV+ disease) remain active, though no protocol has yet changed standard-of-care.
Vulvar, Vaginal, and Penile Cancers
A prospective Danish cohort (n=455,349) confirmed that hrHPV-positive women have significantly elevated 5-year risks for VIN2+ (0.45%), VaIN2+ (0.14%), and AIN2+ (0.12%), highlighting the need for surveillance protocols in these populations 28. HPV's expanding role in genitourinary malignancies beyond cervical cancer is an active research frontier 21.
Public Health Implementation and WHO Elimination Strategy
The WHO's 90-70-90 targets (90% of girls vaccinated by age 15; 70% of women screened by ages 35 and 45; 90% treated) by 2030 have catalyzed significant global commitments 34. Major financing announcements at the 2nd Global Cervical Cancer Elimination Forum (Bali, June 2025) include Gavi targeting 120 million additional girls by 2030, UNICEF committing USD 10 million toward HPV vaccine programs, and Unitaid pledging cumulative US$130 million for screening and treatment access across 18 countries 35. Modeling from China projects that 9-valent vaccine deployment from 2025 plus 3-yearly screening could eliminate cervical cancer by 2051, averting 3.65 million cases and 173,600 additional HPV-related cancers by 2100 39. Nevertheless, fewer than 5% of women in many LMICs currently receive cervical cancer screening 35, and global vaccine series completion rates remain at only approximately 15% 3.
Future Outlook
Emerging priorities include: therapeutic mRNA vaccines (e.g., mHTV-02, targeting HPV16/18 E6/E7 via lipid nanoparticles, demonstrating robust CD8+ T-cell responses and tumor regression in preclinical models) 8; adoptive T-cell therapies and bifunctional antibodies for HPV-mediated malignancies 25; next-generation broader-valency and L2-based vaccines; DNA methylation-based triage standardization 40; and oral/saliva HPV assays for oropharyngeal cancer surveillance. Resolving the immunologically "cold" phenotype of most advanced HPV-associated cancers 16 through combination immunotherapy strategies remains a central unmet clinical need.
Human papillomavirus-associated cancers represent a paradigmatic, largely preventable global health problem. Integrating equitable vaccine deployment, high-performance screening including self-collection, and increasingly precision-targeted systemic therapies remains the cornerstone of elimination efforts through 2030 and beyond.